6-Feb-2026
Natera Embarks on Pioneering EDEN Study to Transform Early Risk Assessment for Preeclampsia
Market Chameleon (Fri, 6-Feb 4:28 AM ET)
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
Business Wire (Fri, 6-Feb 6:00 AM ET)
Natera Submits Signatera CDx PMA to FDA
Business Wire (Mon, 2-Feb 6:00 AM ET)
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
Business Wire (Wed, 28-Jan 8:00 AM ET)
Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care
Business Wire (Mon, 26-Jan 6:00 AM ET)
Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer
Business Wire (Wed, 21-Jan 6:00 AM ET)
Business Wire (Tue, 20-Jan 6:00 AM ET)
Business Wire (Tue, 13-Jan 8:00 AM ET)
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
Business Wire (Mon, 12-Jan 10:00 AM ET)
Business Wire (Sun, 11-Jan 10:48 PM ET)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera trades on the NASDAQ stock market under the symbol NTRA.
As of February 6, 2026, NTRA stock price climbed to $203.04 with 1,390,388 million shares trading.
NTRA has a beta of 0.88, meaning it tends to be less sensitive to market movements. NTRA has a correlation of 0.14 to the broad based SPY ETF.
NTRA has a market cap of $28.31 billion. This is considered a Large Cap stock.
Last quarter Natera reported $592 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $79 million and missed earnings estimates by -$.27.
In the last 3 years, NTRA traded as high as $256.36 and as low as $36.90.
The top ETF exchange traded funds that NTRA belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
NTRA has outperformed the market in the last year with a return of +15.9%, while the SPY ETF gained +15.1%. However, in the most recent history, NTRA shares have underperformed the stock market with its stock returning +2.3% in the last 3 month period and -16.0% for the last 2 week period, while SPY has returned +3.3% and +0.2%, respectively.
NTRA support price is $191.06 and resistance is $203.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTRA shares will trade within this expected range on the day.
